Empowering the CRISPR/Cas9 platform globally

The CRISPR patent portfolio licensed via ERS (known as the CVC portfolio) is the most comprehensive collection of proprietary rights to the fundamental CRISPR/Cas9 gene editing platform. Built on the Nobel Prize winning work of Emmanuelle Charpentier and Jennifer Doudna, ERS grants non-exclusive licenses to a growing list of issued and pending patent applications globally, in all fields excluding direct use as a human therapeutic.

ERS’s collaborative licensing approach promotes widespread adoption of CRISPR/Cas9 technology.

Non-exclusive licenses are available to companies involved in development and commercialization of CRISPR/Cas9 technology, products, and services.

Licenses are available in a wide range of fields

  • Pharmaceutical & Biotechnology
  • CROs, CMOs & Tool Providers
  • Companion Animal & Veterinary Applications
  • Agriculture & Livestock applications
  • Industrial & Synthetic Biology Applications

Some of our 100+ Licensees

Internal
Research
Industrial Bio
Production
CRO’s
CMO’s
Tools /
Reagents